 - Specific Aim 3 THIS STUDY: Evaluate the impact of dose adjustment of protease inhibitors based on pharmacogenetic profile and virtual inhibitory quotient VIQ on clinical outcome measured by HIV-RNA viral load and CD4 cell count changes and toxicity graded by the DAIDS classification in pediatric patients with HIV infection. 